You need to enable JavaScript to run this app.
Recon: Baxter in late-stage talks for $10B Hillrom buy; Catalent drops $1B for gummy vitamin maker
Recon
Kari Oakes
Biologics/ biosimilars/ vaccines
Global
Medical Devices
Pharmaceuticals
Regulatory Intelligence/Policy